ENTA · Enanta Pharmaceuticals, Inc.

0001193125-26-220572

Summary

Enanta's Q2 FY2026 loss narrowed significantly as higher HCV royalty revenue and cost controls offset ongoing pipeline investment.

Key takeaways

Revenue rose 15% to $17.2M, driven by higher AbbVie HCV sales.
Operating loss improved 52% to -$11.9M, reflecting lower R&D and legal costs.
Net loss narrowed 42% to -$13.1M, with diluted EPS improving to -$0.45 from -$1.06.
Operating cash outflow improved to -$18.9M from -$30.3M, while free cash flow was -$19.0M.
Management expects existing liquidity to fund operations into fiscal 2029.

Full analysis

Revenue Growth Driven by AbbVie HCV Sales

Operating Loss Narrows on Cost Discipline

Cash Flow and Liquidity Position

Pipeline Progress and Outlook

Enanta continues to advance its wholly-owned programs and expects to generate operating losses for the foreseeable future. The company's cash position is expected to support at least 12 months of operations from the balance sheet date. The CODM evaluates performance on a consolidated basis, allocating capital and personnel accordingly.